On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
immune-checkpoint-inhibitors
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
immune-checkpoint-inhibitors
CAR immune Cell therapyChimeric Antigen Receptor (CAR) immune cell therapy has transformed the treatment of cancer, especially for hematological cancers. Its effectiveness notwithstanding, it still ...
immune-checkpoint-inhibitors